Business Context and Reporting Period
This Form 8-K is filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on August 8, 2022, with the earliest event reported on August 8, 2022. The filing primarily addresses significant changes in executive leadership and board composition, alongside the announcement of financial results for the quarter ended June 30, 2022.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing earnings results for the quarter ended June 30, 2022. However, the text of this 8-K does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release or the company's quarterly report for these figures.
Material Changes and Corporate Actions
- Executive Departure: Kevin Farr was terminated without cause as Chief Financial Officer, effective August 12, 2022.
- Interim CFO Appointment: Brianna Gerber was appointed SVP, Finance / Interim Chief Financial Officer, effective August 11, 2022.
- Board Appointment: Hamed Shahbazi was appointed to the Board of Directors, effective August 9, 2022, and assigned to the Nominating and Corporate Governance Committee.
Compensation, Guidance, and Risks
Compensation Arrangements
- Brianna Gerber (Interim CFO):
- Annual base salary: $300,000.
- Discretionary bonus opportunity: 40% of base salary.
- Equity: Stock options and restricted stock units (RSUs) valued at $113,750 each, with specific vesting schedules tied to continuous employment.
- Hamed Shahbazi (Director):
- Annual retainer: $40,000, plus $5,000 for committee service.
- Equity: Initial grant of 40,000 stock options vesting over three years; annual grants of 20,000 options vesting over one year.
- Kevin Farr (Outgoing CFO):
- Severance package includes 89,189 RSUs, a lump sum payment of $30,442, acceleration of certain unvested equity awards, and a pro rata bonus.
- Agreement includes a 90-day transition consulting period.
Outlook and Risks
The filing does not contain specific forward-looking guidance or risk factors beyond the standard disclosure that the information is furnished and not "filed" for liability purposes under Section 18 of the Exchange Act. The departure of the CFO and the appointment of an interim successor represent a material operational change that investors should monitor.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q2 2022 financial results (revenue, net income, cash flow).
- Verify the terms of the "Farr Agreement" and "Consultant Agreement" (Exhibits 10.1 and 10.2) to understand the full scope of severance liabilities.
- Monitor the transition period for the CFO role to ensure continuity in financial reporting and investor relations.
- Confirm the impact of the new board member, Hamed Shahbazi, on corporate governance and strategic direction.